Lineage Cell Therapeutics Inc
XBER:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lineage Cell Therapeutics Inc
XBER:BT3
|
US |
|
I
|
Itafos
OTC:MBCF
|
KY |
|
CNB Financial Corp
NASDAQ:CCNE
|
US |
|
A
|
Appen Ltd
OTC:APPEF
|
AU |
|
N
|
News Corp
NASDAQ:NWS
|
US |
|
FILA Fabbrica Italiana Lapis ed Affini SpA
MIL:FILA
|
IT |
|
C
|
CNOOC Ltd
XBER:NC2B
|
CN |
|
UPL Ltd
LSE:UPLL
|
IN |
|
P
|
PennyMac Mortgage Investment Trust
F:8PM
|
US |
|
B
|
Banco Santander SA
VSE:SAN
|
ES |
|
M
|
Man Wah Holdings Ltd
XBER:AAM
|
HK |
|
Panin Financial Tbk PT
F:OHH
|
ID |
|
C
|
Champion Iron Ltd
F:MMPI
|
AU |
|
U
|
United Therapeutics Corp
F:UTH
|
US |
|
Karooooo Ltd
NASDAQ:KARO
|
SG |
|
M
|
McCormick & Company Inc
DUS:MCX
|
US |
|
Daikin Industries Ltd
TSE:6367
|
JP |
|
S
|
Sonic Healthcare Ltd
XBER:SAB
|
AU |
|
A
|
Avacta Group PLC
F:RTQ1
|
UK |
|
Deere & Co
NYSE:DE
|
US |
Wall St Price Targets
BT3 Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BT3 is 6.32 EUR with a low forecast of 3.41 EUR and a high forecast of 10.65 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
6.32
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 6.32 EUR with a low forecast of 3.41 EUR and a high forecast of 10.65 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 74%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 74%.
